

Contents

List of Contributors *XI*

Preface *XV*

1	Biomarkers – Past and Future	1
	<i>Siegfried Neumann</i>	
1.1	Introduction	1
1.2	Definitions of Biomarkers	2
1.3	Biomarkers in the Past	3
1.4	Novel Molecules and Structural Classes of Biomarkers by New Technologies	7
1.5	Biomarkers in Drug Research	9
1.6	Current Development and Future Trends for Biomarkers in Laboratory Diagnostics	12
1.6.1	Biomarker Test Validation	12
1.6.2	Companion Diagnostics in Clinical Pharmacology	14
1.6.3	Biomarker Multivariate Index Assays	16
1.6.4	Regulatory Policies on Biomarker Tests	17
1.7	Summary and Outlook	19
	References	20
2	Quantitative Proteomics Techniques in Biomarker Discovery	23
	<i>Thilo Bracht, Dominik Andre Megger, Wael Naboulsi, Corinna Henkel, and Barbara Sitek</i>	
2.1	Introduction	23
2.1.1	General Considerations	24
2.2	2D-Difference Gel Electrophoresis	27
2.3	Mass Spectrometry-Based Proteomics	29
2.3.1	Principles and Instrumentation	29
2.3.1.1	Ionization Methods	29
2.3.1.2	Mass Analyzers	30
2.3.2	Label-Free Protein Quantification	30
2.3.2.1	Area Under Curve (AUC) or Signal Intensity Measurement	30
2.3.2.2	Spectral Counting	31

2.3.3	Label-Based Proteome Analysis	31
2.4	MALDI Mass Spectrometry Imaging	33
2.5	Conclusion	36
	References	36
3	Biomarker Qualification: A Company Point of View	39
	<i>Maximilian Breitner, Kaidre Bendjama, and Hüseyin Firat</i>	
3.1	Introduction	39
3.2	Biomarker Uses	40
3.3	Biomarker Types	41
3.4	Validation vs. Qualification	43
3.5	Strategic Choices in Business Models	43
3.6	Validation of Analytical Methods	44
3.6.1	Currently Applicable Guidelines for the Validation of Analytical Methods	45
3.6.2	Laboratory Proficiency	46
3.6.3	Establishment of Reference Ranges for Candidate Biomarkers	46
3.7	Clinical Qualification of Candidate Biomarkers	47
3.7.1	Methodological Approaches	47
3.7.2	Study Size for Biomarker Performance Characterization	48
3.7.3	Sample Quality and Biobanking	50
3.7.3.1	Sample Collection	50
3.7.3.2	Storage of Sample	51
3.7.3.3	Clinical Data (Sample Annotation)	52
3.7.3.4	Ethical Considerations	53
3.8	Biomarker Qualification in the 'omics Era	53
3.9	An Example of a Biomarker Provider	54
3.10	Conclusion	55
	References	55
4	Biomarker Discovery and Medical Diagnostic Imaging	59
	<i>Andreas P. Sakka and James R. Whiteside</i>	
4.1	Introduction	59
4.1.1	Imaging Modalities	59
4.1.1.1	Positron Emission Tomography (PET)	59
4.1.1.2	Single Photon Emission Computed Tomography (SPECT)	60
4.1.1.3	Computed Tomography (CT)	60
4.1.1.4	Magnetic Resonance Imaging (MRI)	60
4.1.1.5	Ultrasound (US)	61
4.2	Factors to Consider in Biomarker Selection for Imaging	61
4.3	Defining the Insertion Point of the Assay and Its Business Case	62
4.4	Practical <i>In Vitro</i> Methods Used to Identify Biomarkers	63
4.5	Preclinical Models	64
4.5.1	Model Species	64

4.5.2	Inducing Human Disease and Relevant Biomarker Expression	64
4.5.3	Genetic Manipulation	65
4.5.4	Pharmacological/Chemical Induction	65
4.5.5	Xenografts: Grafting Foreign Cells or Tissues	66
4.5.6	Physical Induction	66
4.6	Preclinical Analysis Techniques	67
4.7	Translational Considerations and Restrictions	67
4.8	Other Uses of Preclinical Models	68
4.9	Nuclear Imaging Infrastructure	69
4.10	Image Processing	70
4.11	Concluding Remarks	70
	References	71
5	Breath: An Often Overlooked Medium in Biomarker Discovery	75
	<i>Jonathan D Beauchamp and Joachim D Pleil</i>	
5.1	Introduction	75
5.1.1	Breath Analysis: Past and Present	76
5.2	Breath Analysis Studies: Targets, Techniques, and Approaches	77
5.2.1	Exhaled Breath Gas, Condensate, and Aerosols	79
5.2.2	Sampling Techniques and Analytical Tools	80
5.2.3	Discovery Versus Targeted Study Approaches	81
5.3	Biomarker Confounders	83
5.3.1	Sampling Impact	83
5.3.1.1	Online Breath Sampling and Direct Analysis	84
5.3.1.2	Breath Sampling for Offline Analysis	84
5.3.2	Contributions from the Exposome	85
5.4	Biomarkers in Breath	86
5.4.1	Inorganic Breath Biomarkers	86
5.4.2	Organic Biomarkers in Breath	87
5.5	Outlook for Breath Analysis	88
	Acknowledgments	90
	References	90
6	HTA in Personalized Medicine Technologies	95
	<i>Franz Hessel</i>	
6.1	Introduction	95
6.2	Health Technology Assessment (HTA)	96
6.3	Validation and Evaluation of Biomarker Tests	99
6.4	Health Technology Assessment of Personalized Medicine Technologies	100
6.5	Concluding Remarks	104
	References	105

7	Bone Remodeling Biomarkers: New Actors on the Old Cardiovascular Stage	107
	<i>Cristina Vassalle, Silvia Maffei, and Giorgio Iervasi</i>	
7.1	Introduction	107
7.2	Cardiovascular Disease and Osteoporosis: Common Risk Factors and Common Pathophysiological Mechanisms	108
7.3	Biomarkers of Bone Health in CVD	112
7.3.1	Cathepsin K	112
7.3.2	Tartrate-Resistant Acid Phosphatase	115
7.3.3	Sclerostin	115
7.3.4	Fibroblast Growth Factor 23	116
7.3.5	Osteopontin	116
7.3.6	Osteocalcin	117
7.3.7	Osteoprotegerin	118
7.3.8	Vitamin D	120
7.3.9	Other Factors	121
7.3.10	Genetic Factors	123
7.4	Conclusion	125
	References	128
 8	 Identification and Validation of Breast Cancer Biomarkers	 147
	<i>Kori Jackson and Edward Sauter</i>	
8.1	Introduction	147
8.2	Current Detection and Treatment Modalities	148
8.2.1	Detection: In Clinical Use	148
8.2.1.1	Physical Examination	148
8.2.1.2	Breast Imaging	148
8.2.2	Detection: Being Evaluated	149
8.2.2.1	Bodily Fluid Analyses	150
8.2.3	Treatment: In Clinical Use	150
8.2.3.1	Surgery and Radiation	150
8.2.3.2	Systemic Therapy	151
8.2.4	Treatment: Being Evaluated/Newly Available	153
8.2.4.1	Biomarkers in Tissue: Single Markers	153
8.2.4.2	Biomarkers in Tissue: Gene Panels	154
8.3	Current Biomarker Limitations	154
8.3.1	Tumor Heterogeneity	154
8.3.2	Treatment Effect	155
8.3.3	Primary Versus Recurrent Tumor	155
8.4	Future Biomarker Discovery Targets	156
8.4.1	Autoantibodies	156
8.4.2	Inflammatory Markers	156
8.4.3	DNA Methylation	157
8.4.4	Benign Breast Disease	157
8.4.5	Pregnancy-Associated Breast Cancer	157

8.4.6	Challenges with New Biomarker Development and Validation	157
8.4.7	Sample Type Selection for Validation Studies of Diagnostic Biomarkers	158
8.4.7.1	Why Ductal Lavage for DNA Analysis?	158
8.4.7.2	Why Nipple Aspirate Fluid for Protein Analysis?	158
8.4.7.3	Why Circulating Samples for Protein Analysis?	158
8.4.7.4	DNA Candidates	159
8.4.7.5	RNA Candidates	159
8.4.7.6	Protein Candidates	159
8.5	Summary	160
	References	161

9 Evaluation of Proteomic Data: From Profiling to Network Analysis by Way of Biomarker Discovery 163

Dario Di Silvestre, Francesca Brambilla, Sara Motta, and Pierluigi Mauri

9.1	Introduction	163
9.2	Proteomic Methodologies	164
9.3	Shotgun Proteomics	165
9.3.1	Targeted Proteomics	168
9.3.2	Data-Independent Acquisition (DIA) MS	169
9.4	Biomarker Discovery	170
9.4.1	MudPIT Data Processing	172
9.5	Protein-Protein Interaction Network Analysis	174
9.6	Conclusion	176
	References	177

10 Biomarkers: From Discovery to Commercialization 183

Sebastian Hoppe and Henry Memczak

10.1	Comparison of Different Platforms	184
10.2	Mass Spectrometry	185
10.3	Enzyme-Linked Immunosorbent Assay	187
10.4	SPR Imaging	188
10.5	Reverse Phase Protein Microarrays	189
10.6	Next-Generation Sequencing (NGS)	190
10.7	Still a Struggle: Achieving Clinical Trial Status	193
10.8	Commercial Biomarker Assays	195
10.9	Quo Vadis, Biomarker Assays?	197
	References	199

11 Clinical Validation 207

Mads Almose Røpke

11.1	Introduction	207
11.2	Classification of Biomarkers	208
11.3	Translational Use of Biomarkers	209
11.4	Biomarkers in Clinical Studies	210

11.4.1	Healthy Volunteer Studies	210
11.4.2	Early Patient Studies	211
11.4.3	Confirmatory Clinical Studies	214
11.4.4	Enrichment Design	215
11.4.5	Biomarker-Stratified Design	216
11.5	Safety Markers in Clinical Development	216
11.6	Statistical Considerations	218
11.7	Validation	218
11.8	Regulatory Considerations for Implementation of Biomarkers in Clinical Studies	221
11.9	Biorepositories and Ethics	222
11.10	Conclusion	224
	References	225

12 Genomics and Proteomics for Biomarker Validation 231

Paula Díez, Rosa M^a Dégano, Nieves Ibarrola, Juan Casado, and Manuel Fuentes

12.1	Introduction	231
12.1.1	Biomarker Discovery	233
12.2	Challenges in Biomarker Discovery/Verification Phases	234
12.3	Verification of Biomarkers	235
12.3.1	Protein Binding Assays	235
12.3.2	Targeted Proteomics	237
12.3.3	Correlation Between MRM and ELISA	237
12.3.4	MRM and Biomarker Pipeline	238
12.4	Role of Biobanking in Biomarkers Validation	238
12.4.1	Biobanking Challenges Associated with Biomarker Discovery and Validation	239
12.4.1.1	Preanalytical Variations and Lack of SOPs	239
12.4.1.2	Biological Diversities	239
12.4.1.3	Disease Heterogeneity	239
12.4.1.4	Technical Limitations	240
12.4.1.5	Validation and Clinical Trials	240
12.4.1.6	Lack of Stable Biorepository	240
12.5	Conclusions	240
	References	241

Index 243